Analysis of the possibility and progress of FoxP3 in tumor treatment based on its effect on Tregs

Abstract. Treg can inhibit immunity in cancer and a variety of autoimmune diseases. And foxp3 is a kind of spectrum specificity markers. Its also the main regulatory factor that can ensure the generation, maintenance and the immunosuppressive function of the Treg cells. At the same time, foxp3 can also promote the differentiation and function of Treg. In this paper, the interaction between foxp3 and various transcription factors (TFs) as well as their joint action are analyzed. These effects can have an impact on the suppressive effect of Treg cells, which in turn affects the status of the tumor. The post-translational modifications of foxp3 itself are also analyzed. foxp3 has been modified by methylation, acetylation, phosphorylation, ubiquitination, glycosylation and lactatation. Its own activity has been affected, and its binding ability to target genes has been changed. From these analyses, a conclusion can be drawn that the effect of CAR-T therapy can be enhanced by targeting multiple TFs and signaling pathways. At the same time, targeted inhibitors can be explored for various enzymes involved in post-translational modification. And these inhibitors can reduce the ability of foxp3. However, the research on TFs and post-translational modifications still has some limitations. Future studies can focus on these two aspects.